Valbiotis SA (ALVAL.PA)
Paris · EUR · Consumer Defensive · Packaged Foods
€0.576 (+2.86%) as of
Key statistics
- Market cap
- 20.44M
- Forward P/E
- -7.20
- EPS (TTM)
- -0.3200
- Dividend yield
- 0.00%
- 52-week range
- 0.4860 – 1.2960
- Beta
- -0.14
- Revenue (TTM)
- 1.34M
- Profit margin
- 0.00%
- Analyst target
- €1.60
- Volume
- 62.14k
About Valbiotis SA
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Headquarters
- Périgny, France
- Employees
- 50
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.